%0 Journal Article
%T Temporal and spatial variability of immunosuppressive therapies in transplant patients: An observational study in Italy.
%A Marino ML
%A Rosa AC
%A Finocchietti M
%A Bellini A
%A Poggi FR
%A Massari M
%A Spila Alegiani S
%A Masiero L
%A Ricci A
%A Bedeschi G
%A Puoti F
%A Cardillo M
%A Pierobon S
%A Nordio M
%A Ferroni E
%A Zanforlini M
%A Piccolo G
%A Leoni O
%A Ledda S
%A Carta P
%A Garau D
%A Lucenteforte E
%A Davoli M
%A Addis A
%A Belleudi V
%J Front Transplant
%V 1
%N 0
%D 2022
%M 38994384
暂无%R 10.3389/frtra.2022.1060621
%X <B>UNASSIGNED: </B>In immunosuppression after transplantation, several multi-drug approaches are used, involving calcineurin inhibitors (CNI: tacrolimus-TAC or cyclosporine-CsA), antimetabolites (antiMs), mammalian target of rapamycin inhibitors (mTORis), and corticosteroids. However, data on immunosuppressive therapy by organ and its space-time variability are lacking.<BR><B>UNASSIGNED: </B>An Italian multicentre observational cohort study was conducted using health information systems. Patients with incident transplant during 2009-2019 and resident in four regions (Veneto, Lombardy, Lazio, and Sardinia) were enrolled. The post-transplant immunosuppressive regimen was evaluated by organ, region, and year.<BR><B>UNASSIGNED: </B>The most dispensed regimen was triple-drug therapy for the kidneys [tacrolimus (TAC) + antiM + corticosteroids = 41.5%] and heart [cyclosporin  + antiM + corticosteroids = 36.6%] and double-drug therapy for liver recipients (TAC + corticosteroids = 35.4%). Several differences between regions and years emerged with regard to agents and the number of drugs used.<BR><B>UNASSIGNED: </B>A high heterogeneity in immunosuppressive therapy post-transplant was found. Further studies are needed in order to investigate the reasons for this variability and to evaluate the risk-benefit profile of treatment schemes adopted in clinical practice.